Key result
Higher apolipoprotein C-II truncation linked to ~11% lower CHD risk per SD.
Why the study?
The prospective relationships of truncated-to-native proteoform ratios of apolipoproteins C-I and C-II with coronary heart disease and coronary artery calcium progression were unclear.
Cohort (n=5,790)
Hazard Ratio: 0.89 (95% CI 0.81–0.98)
Higher apoC-I/II proteoform ratios may mark lower CHD risk; leaves open incremental prognostic value and causality beyond standard lipids.
BACKGROUND AND AIMS: Higher truncated-to-native proteoform ratios of apolipoproteins (apo) C-I (C-I'/C-I) and C-II (C-II'/C-II) are associated with less atherogenic lipid profiles. We examined prospective relationships of C-I'/C-II and C-II'/C-II with coronary heart disease (CHD) and coronary artery calcium (CAC). METHODS: ApoC-I and apoC-II proteoforms were measured by mass spectrometry immunoassay in 5790 MESA baseline plasma samples. CHD events (myocardial infarction, resuscitated cardiac arrest, fatal CHD, n = 434) were evaluated for up to 17 years. CAC was measured 1-4 times over 10 years for incident CAC (if baseline CAC = 0), and changes (follow-up adjusted for baseline) in CAC score and density (if baseline CAC>0). RESULTS: C-II'/C-II was inversely associated with CHD (n = 434 events) after adjusting for non-lipid cardiovascular risk factors (Hazard ratio: 0.89 [95% CI: 0.81-0.98] per SD), however, the association was attenuated after further adjustment for HDL levels (0.93 [0.83-1.03]). There was no association between C-I'/C-I and CHD (0.98 [0.88-1.08]). C-II'/C-II was positively associated with changes in CAC score (3.4% [95%CI: 0.6, 6.3]) and density (6.3% [0.3, 4.2]), while C-I'/C-I was inversely associated with incident CAC (Risk ratio: 0.89 [95% CI: 0.81, 0.98]) in fully adjusted models that included plasma lipids. Total apoC-I and apoC-II concentrations were not associated with CHD, incident CAC or change in CAC score. CONCLUSIONS: Increased apoC-II truncation was associated with reduced CHD, possibly explained by differences in lipid metabolism. Increased apoC-I and apoC-II truncations were also associated with less CAC progression and/or development of denser coronary plaques.
No takes yet. Share an insight, caveat, or question.
Koška et al. (2023) conducted a cohort in Coronary heart disease and coronary artery calcium (n=5,790). Apolipoprotein C-I and C-II truncations (C-I'/C-I and C-II'/C-II ratios) was evaluated on Coronary heart disease (CHD) events (HR 0.89, 95% CI 0.81-0.98). Higher apolipoprotein C-II truncation (C-II'/C-II) was inversely associated with coronary heart disease (HR 0.89; 95% CI 0.81-0.98 per SD), though attenuated after adjusting for HDL levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: